Clinical trials of immunoadsorbent in systemic lupus erythematosus therapy.
Five patients with systemic lupus erythematosus (SLE) were perfused through an extracorporeal shunt filled with DNA-immunoadsorbent (DNA immobilized on carbonized resin beads). High concentrations of anti-DNA antibodies (36.4-67.0%) (binding percentage with 125I-DNA) in the serum of SLE patients were reduced to 13.8-53.0%, respectively. The highest removal percentage was 62.1%. Although the decline levels varied, the symptoms of patients, i.e., long-term severe joint pain, severe edema, hydropericardium, and ascites were all relieved considerably. The immunoadsorbent showed satisfactory blood compatibility.
Gao
C L
CL
Institute for Molecular Biology, Nankai University, Tianjin, China.
Li
B A
BA
Chen
C Z
CZ
Yu
Y T
YT
Yuan
P
P
Song
J C
JC
D000974:Antibodies, Antinuclear / Q000097:blood; D006464:Hemoperfusion; D006801:Humans; D007163:Immunosorbent Techniques; D007164:Immunosorbents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000628:therapy*
D000974:Antibodies, Antinuclear; D007164:Immunosorbents